Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Osteoblastic progression during EGFR tyrosine kinase inhibitor therapy in mutated non-small cell lung cancer: a potential blunder.

Tumori - 21 Jan 2017

Bersanelli Melissa, Bini Paola, Rabaiotti Enrico, Facchinetti Francesco, De Filippo Massimo, Bortesi Beatrice, Buti Sebastiano, Tiseo Marcello

Abstract excerpt

AIMS AND BACKGROUND: Bone flare reaction as a sign of response to antineoplastic treatment has been redefined, including the onset of new osteoblastic lesions. If misunderstood as skeletal progression, this finding could lead to erroneous therapy discontinuation, changing the disease clinical course. We aim to describe this clinical phenomenon in patients with advanced non-small cell lung cancer (NSCLC) with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to EGFR gene

Share to Lung Neoplasms

Share to Mutation

Share to Osteoblasts

Share to Tomography, X-Ray Computed

Source

Identifiers

PMID: 26391764
DOI: 10.5301/tj.5000423

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Osteoblastic progression during EGFR tyrosine kinase inhibitor therapy in mutated non-small cell lung cancer: a potential blunder.PMID 26391764Read ↗

Osteoblastic bone lesions developing during treatment with erlotinib indicate major response in patients with non-small cell lung cancer: a brief report.Semantic proximity Read ↗

Osteoblastic reaction in non-small cell lung carcinoma and its association to epidermal growth factor receptor tyrosine kinase inhibitors response and prolonged survival.Semantic proximity Read ↗

Osteoblastic bone reaction in non-small cell lung cancer harboring epidermal growth factor receptor mutation treated with osimertinib.Semantic proximity Read ↗

Osteoblastic response in patients with non-small cell lung cancer with activating EGFR Mutations and bone metastases during treatment with EGFR kinase inhibitors.Semantic proximity Read ↗

Osteosclerotic Change as a Therapeutic Response to Gefitinib in Symptomatic Non-Small Cell Lung Cancer Bone MetastasisSemantic proximity Read ↗

Osteosclerotic change as a therapeutic response to gefitinib in symptomatic non-small cell lung cancer bone metastasis.Semantic proximity Read ↗

Clinical Implications of Isolated Bone Failure Without Systemic Disease Progression During EGFR-TKI Treatment.Semantic proximity Read ↗

Relationship between clinical features and gene mutations in non-small cell lung cancer with osteoblastic bone metastasis.Semantic proximity Read ↗

Tumor-free osteosclerotic lesions in patients treated for metastatic melanoma using BRAF inhibitors.Semantic proximity Read ↗

Prediction of skeletal-related events in patients with non-small cell lung cancer.Semantic proximity Read ↗

Skeletal-related events in advanced lung adenocarcinoma patients evaluated EGFR mutations.Semantic proximity Read ↗

Prolonged control of bone metastases in non-small-cell lung cancer patients treated with gefitinib.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.